Acute Myeloid Leukemias, Advanced Hematological Malignancies, Indication for Allogeneic Stem Cell Transplantation, no HLA-identical Donor Available
Conditions
Brief summary
Experimental and clinical data suggest that alloreactive NK cells can reduce the risk of graft-rejection, GvHD and leukemic relapse after HLA-mismatched transplantation. The effectiveness of allogeneic NK cells is a function of HLA-differences between donor and recipient that give rise to NK cell clones which do not express inhibitory receptors matching for the HLA molecules of the recipient. Aim of the study is to evaluate cellular therapy with alloreactive, IL-2 activated NK cells after transplantation of T-cell depleted stem cell grafts from one haplotype mismatched family donors in patients with hematological malignancies.
Interventions
BIOLOGICALHaploidentical transplantation with donor NK cells
Pat received a myeloablative conditioning regimen with 12 Gy total-body irradiation in six single doses from day -11 to day -9, thiotepa (5mg/kg/d) on days -8 and -7, fludarabine (40mg/m2/d) from day -6 to day -3, and OKT-3 (5mg/d) from day -5 to day +3. The stem cell graft was aimed to contain \> 8 x 10e6 CD34+ cells/kg and \< 5 x 10e4 CD3+ cells/kg. A minimum of 1 x 10e7 CD56+CD3- NK cells/kg will be transferred on days +2.
Sponsors
University of Leipzig
Charite University, Berlin, Germany
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 54 Years
Healthy volunteers
No
Inclusion criteria
* Patients with AML or ALL in first CR with the following high risk features: 1. AML with aberration Del (5q) -5, del (7q) -7, t(9;22) or t(6;9), abn 3q, 9q, 11q, 20q, 21q, 17p; 2. AML with a complex caryotype; 3. secondary AML after previous chemo- or radiotherapy or MDS; 4. Ph-positive ALL * Patients with AML or ALL after induction failure or in second CR * Patients with CML in second chronic or accelerated phase * Patients with malignant Lymphoma and the following high risk features: 1. relapse after autologous transplantation 2. primary chemotherapy refractory disease * All patients must fulfill the following criteria: 1. lack of a suitable HLA-identical family, unrelated or cord blood donor 2. no active infection, no severe impairment of cardial, pulmonary, renal and hepatic function 3. blast count in the marrow \< 30% 4. informed consent
Exclusion criteria
* active infection, no severe impairment of cardial, pulmonary, renal and hepatic function * blast count in the marrow \> 30% * unable or unwilling to sign and/or understand informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate feasibility and safety of alloreactive CD56+/CD3- donor NK cells after one haplotype mismatched transplantation | 1 year | To evaluate feasibility and safety of cellular immunotherapy with purified alloreactive CD56+/CD3- donor NK cells after one haplotype mismatched hematopoietic stem cell transplantation in patients with high risk hematological malignancies who lack an HLA-identical donor. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| transplant related mortality | 1 year | The investigation of transplant related mortality (incidence of veno occlusive disease; incidence and type of infectious complications). |
| effectiveness | 2 years | To evaluate the effectiveness of the therapy (relapse rate; disease free survival; MRD monitoring). |
| technical aspects of the cell separation procedure | 7 days | To investigate technical aspects of the cell separation procedure (problems of stem cell mobilization; yield, viability, sterility and purity of the CD34+ and CD56+CD3- cell fraction; log CD3 depletion; in vitro anti-leukemic activity of the CD56+CD3- cell fraction). |
| stable engraftment of haploidentical stem cell grafts can be achieved after conditioning with total body irradiation, thiotepa, fludarabine and OKT3 and subsequent transfer of megadoses of positively selected CD34+ stem cells and CD56+CD3- NK-cells. | 28 days | Graft rejection is defined as neutrophils \< 0.5 x 10e9/l on day+28 post transplantation. |
Countries
Germany
Contacts
Primary ContactLutz Uharek, MD
Backup ContactBirte Friedrichs, MD
Outcome results
None listed